The mission of RevMAb Biosciences USA, Inc is to promote personal health by accelerating biomedical research and advancing disease diagnosis.

RevMAb seek to accomplish this by providing superior monoclonal antibodies. The team consists of pioneers in optimizing and transforming rabbit hybridoma technology for commercial application, and developing rabbit monoclonal antobodies for research, diagnostic and therapeutic use.

“Revolutionary mAb Technology,,

RevMAb has developed a monoclonal antibody generation method which allows development of monoclonal antibodies without generation of hybridoma. The recombinant antibodies are developed from a broad range of antigen-specific B cells that are inaccessible to traditional hybridoma technology. This method has successfully been applied to develop high quality recombinant rabbit and goat monoclonal antibodies.

Instead of current hybridoma generation by cell fusion methods, RevMAb directly screens antibodies from immunized rabbit or goat B cells by immunoassays such as ELISA, Western Blot, etc. and identifies desired B cells. Then RevMAb clones cDNA and performs recombinant antibody production using transient and stable mammalian cell expression.

For more information about the RevMAb portfolio of primary and secondary antibodies, please contact Sanbio.